Oncotelic Therapeutics, Inc. filed its 10-K on Apr 14, 2023 for the period ending Dec 31, 2022. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0379 USD | -9.83% | -3.81% | -1.04% |
1st Jan change | Capi. | |
---|---|---|
-1.04% | 16.79M | |
-2.19% | 103B | |
+1.76% | 95.28B | |
+1.46% | 22.15B | |
-15.72% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.17% | 16.05B | |
+4.74% | 13.68B | |
+36.41% | 12.17B |
- Stock Market
- Equities
- OTLC Stock
- News Oncotelic Therapeutics, Inc.
- Oncotelic Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt